Hospitalization for status epilepticus seizures rose from 2010 to 2019, disproportionately affecting Black patients, U.S. inpatient data showed. The overall prevalence of status epilepticus ...

PHILADELPHIA -- Continuous infusions for refractory status epilepticus may be more harmful than intermittent doses of drugs, researchers reported here. In a prospective cohort study, children who ...

Status epilepticus is a medical emergency associated with significant morbidity and mortality. It is defined as "a single epileptic seizure of >30-min duration or a series of epileptic seizures during ...

Clinicians often face a dilemma about whether to perform lumbar puncture in a child with a prolonged febrile seizure or fever-associated status epilepticus. To determine whether status epilepticus ...

Early termination of prolonged seizures with intravenous administration of benzodiazepines improves outcomes. For faster and more reliable administration, paramedics increasingly use an intramuscular ...

A surprisingly high rate of nonconvulsive seizures and status epilepticus is found during continuous EEG monitoring in critically ill patients. A recent analysis of data regarding hospitalization and ...

Emergency department care of Established Status Epilepticus (ESE) in the US is not the same everywhere. Doctors use their judgment, but what treatment will work best is not known. The purpose of this ...

Please provide your email address to receive an email when new articles are posted on . A Bay Area neurotechnology firm has announced the commercial release of a novel artificial intelligence-based ...

Research carried out in Marburg, Germany indicates that an episode of status epilepticus after stroke is associated with increased long-term mortality. Data from a prospective epidemiological study of ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to PharmaTher for its status epilepticus ketamine treatment, according ...

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...